Ignite Creation Date:
2024-05-05 @ 7:28 PM
Last Modification Date:
2024-10-26 @ 9:49 AM
Study NCT ID:
NCT00670592
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2008-04-30
Brief Title:
Study of HCD122 in Adults With Non-Hodgkins or Hodgkins Lymphoma Who Have Progressed After at Least Two Prior Therapies
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase IAII Multi-center Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkins or Hodgkins Lymphoma Who Have Progressed After at Least Two Prior Therapies CHIR-1212-LYM-01
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to evaluate the highest tolerated dose safety and activity of HCD122 in adults with non-Hodgkins or Hodgkins lymphoma who have received at least two prior therapies
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007-004888-22 | EUDRACT_NUMBER | None | None |